samples were immediately transferred to sterile microtubes and stored at Ϫ70°C until assayed. Case histories were recorded; none of the Bell's palsy patients or the controls had any other known herpesviral infections. All patients were investigated in the acute phase, 1 to 7 days after the onset of facial palsy (median, day 2). Thereafter, the patients underwent clinical examination every 3 months until recovery. No medical or other treatment modalities, except lubrication drops for dry eyes, were used. Electroneuronography (ENOG) and pure-tone audiometry were done on all of the patients. Antibodies against Borrelia burgdorferi flagellin were measured from all of the Bell's palsy patients. Two clinically diagnosed HSV keratitis patients and one VZV blepharitis patient served as positive controls. The keratitis patients' tear fluid samples were collected from the affected eye only.
DNA was isolated from 15 l of tear fluid by proteinase K digestion followed by phenol extraction and ethanol precipitation. Two different PCR programs were used for amplification of specific parts of HSV, VZV, and HHV-6. The amplification procedure for HSV and VZV consisted of 40 cycles at 96°C for 10 s, 55°C for 20 s, and 72°C for 20 s, and the procedure for HHV-6 consisted of 40 cycles at 94°C for 30 s, 51°C for 1 min, and 72°C for 1 min. Both programs also consisted of a denaturation step at the beginning (at 95°C for 10 to 13 min), and for both programs the final step was allowed to continue for 5 min. The primers used in PCRs were chosen from the polymerase genes for HSV-1 and HSV-2 as recommended by Piiparinen and Vaheri (8) (5Ј-biotin-AAG GAG GCG CCC AAG CGT CCG-3Ј and 5Ј-TGG GGT ACA GGC TGG CAA AGT-3Ј), for VZV as recommended by Echevarria et al. (2) (5Ј-AGG TAC CAT GAA AAG CGT-3Ј and 5Ј-biotin-GGC ATG TCC CGA TGT GGA AA-3Ј), and from the U67 gene for HHV-6 as recommended by Gopal et al. (4) (5Ј-AAG CTT GCA CAA TGC CAA AAA ACA G-3Ј and 5Ј-biotin-CTC GAG TAT GCC GAG ACC CCT AAT C-3Ј). Positive and negative controls were included in each run. In addition, an internal standard was used for every sample to detect inhibitory samples. The standard included the sites for HHV-6 primers, and the sequence of the amplified fragment was randomized. The amplified products were detected by microplate hybridization.
Hybridization was carried out as described for HSV using luminometric reading (12) . Briefly, PCR products were immobilized to streptavidin-coated microplates and double-stranded products were denatured by alkali. For hybridization specific digoxigenin-labeled oligonucleotide probes were used (5Ј-CCC TCC TCG CGT TCG TCC TCG-3Ј for HSV-1, 5Ј-TCC TCG TCG TCG TCC TTA ATC C-3Ј for HSV-2, 5Ј-ATA ACT CGC TAC CGG AAC GTA TGC CAC AAG-3Ј for VZV, and 5Ј-AAC TGT CTG ACT GGC AAA AAC TTT T-3Ј for HHV-6) in different concentrations: 5 mM for HSV-1, HSV-2, and VZV and 2 mM for HHV-6. The detection of hybridized products was carried out by using antidigoxigenin antibody conjugated with alkaline phosphatase and Lumi-Phos 538 substrate (Lumigen, Southfield, Mich.). The sample was considered positive if the relative light unit signal was Ͼ7-fold higher than the background signal. Altogether 7 out of 82 tear fluid samples (9%) were found to be inhibitory.
HHV-6 DNA was detected by PCR from tear fluid samples in a total of 7 (35%) Bell's palsy patients and in 1 (5%) healthy control (P ϭ 0.044; Fisher's Exact Test) at the time of the sampling. Altogether HHV-6 DNA was detected in 10 out of the total of 40 tear fluid samples (25%) collected from the patients and in 1 (3%) out of 39 tear fluid samples collected from the healthy controls. HHV-6 was found in two tear fluid samples from the same side as the facial palsy, and in four cases HHV-6 was found in the tear fluid of the contralateral eye (Table 1) . At the time of the Bell's palsy diagnosis, ENOG showed no response in three herpesvirus-positive patients (38%), Ͻ50% response in three herpesvirus-positive patients (38%), and 50 to 90% response in two herpesvirus-positive patients (25%) ( Table 1) . Of 12 herpesvirus-negative Bell's palsy patients ENOG showed no response in one patient (8%), Ͻ50% response in one patient (8%) and 50-90% response in ten patients (84%). In one case the ENOG response was also worse on the opposite side, in one case the eye on the paretic side was so dry that it was difficult to obtain a tear fluid sample, and in one case VZV was also found from bilateral tear fluid samples. VZV was found in four tear fluid samples from two Bell's palsy patients (10%) ( Table 1) . One herpesvirus-negative patient had symptoms suggestive of upper respiratory tract infection within 2 weeks prior to the onset of Bell's palsy. Four patients (one HHV-6 positive, one VZV positive, and two herpesvirus negative) had diabetes which was controlled by medication. Pure-tone audiometry was normal or showed no acute changes in all of the patients. Antibodies against B. burgdorferi were not found in any of the patients. Neither HSV-1 nor HSV-2 was found in the tear fluid samples of Bell's palsy patients or of the healthy controls. HSV-1 DNA was found in two tear fluid samples of two clinically diagnosed HSV keratitis patients, and VZV DNA was found in one tear fluid sample of one clinically diagnosed VZV blepharitis patient.
In the present study we found that HHV-6 and VZV were detectable by PCR in the tear fluid samples of Bell's palsy patients. Among 20 Bell's palsy patients there were two patients whose facial paralysis did not recover during the 1-year follow-up period. The tears of one patient were PCR positive for HHV-6, and the tears of the other patient were PCR positive for VZV. Developments in antiviral treatments may offer better therapeutic measures for early treatment of viral Bell's palsy. Of seven HHV-6-positive Bell's palsy patients, one was also positive for VZV. Whether this coinfection of herpesviruses in Bell's palsy influences the course of the disease is not known. A limited number of studies have demonstrated coinfection of the central nervous system with herpesviruses. One study showed herpesvirus coinfection with HSV and HHV-6 by PCR in 7% of patients with central nervous system disease (9) . Among 20 Bell's palsy patients we found two patients positive for VZV. This result confirms earlier studies in which VZV reactivation without cutaneous vesicles has been demonstrated in up to 25% of cases (1, 10) . Recently, VZV DNA has been detected by PCR in oropharyngeal swabs from patients with acute peripheral facial paralysis without zoster lesions in the oral cavity and skin (3).
In conclusion, our results show that HHV-6 DNA can be detected in the tear fluid of a significant number of Bell's palsy patients. Whether this virus plays a role in the etiopathogenesis of Bell's palsy remains to be determined. It is noteworthy that we found VZV DNA in tear fluid samples from two Bell's palsy patients, showing that VZV can be detected in the tear fluid of patients with Bell's palsy without cutaneous vesicles. 
